Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):344-54. doi: 10.4291/wjgp.v5.i3.344.

Perihilar cholangiocarcinoma: Current therapy.

Author information

  • 1Wei Zhang, Lu-Nan Yan, Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

Abstract

Perihilar cholangiocarcinoma, which is a rare primary malignancy, originates from the epithelial cells of the bile duct. Usually invading the periductal tissues and the lymph nodes, perihilar cholangiocarcinoma is commonly diagnosed in the advanced stage of the disease and has a dismal prognosis. Currently, complete hepatectomy is the primary therapy for curing this disease. Perioperative assessment and available surgical procedures can be considered for achieving a negative margin resection, which is associated with long-term survival and better quality of life. For patients with unresectable cholangiocarcinoma, several palliative treatments have been demonstrated to produce a better outcome; and liver transplantation for selected patients with perihilar cholangiocarcinoma is promising and desirable. However, the role of palliative treatments and liver transplantation was controversial and requires more evidence and substantial validity from multiple institutions. In this article, we summarize the data from multiple institutions and discuss the resectability, mortality, morbidity and outcome with different approaches.

KEYWORDS:

Cholangiocarcinoma; Klatskin tumor; Liver transplantation; Surgery; Therapy

PMID:
25133034
[PubMed]
PMCID:
PMC4133531
Free PMC Article

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk